Dr James Wilmott

Research Associate
Melanoma Institute Australia, Central Clinical School

Telephone +61 02 9515 7840

Map

Current research students

Project title Research student
Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. Tuba GIDE
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients Hojabr KAKAVAND
Role of natural killer cells in patients with metastatic melanoma treated with immune checkpoint inhibitors Hansol LEE
Role of natural killer cells in patients with metastatic melanoma treated with immune checkpoint inhibitors Hansol LEE

Selected grants

2016

  • 2016 NSW Premier's Awards for Outstanding Cancer Research - The 'Wildfire' Highly Cited Publication Award; Wilmott J; Cancer Institute New South Wales/NSW Premier's Awards for Outstanding Cancer Research.
  • The mutational landscape of melanoma in adolescents and young adults; Wilmott J; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.
  • Identifying novel therapeutic targets for the treatment of melanoma in adolescents and young adults; Wilmott J; Cancer Institute New South Wales/Early Career Fellowship.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Diagnostic Histopathology, 69(4), 680-686. [More Information]
  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, C., Lambie, D., Wilmott, J., Pinder, A., Pavey, S., Le Cao, K., Akalin, T., Karaarslan, I., Ozdemir, F., Scolyer, R., et al (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell & Melanoma Research, 29(4), 885-898. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Bosisio, F., Wilmott, J., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W., Massi, D., Thompson, J., Scolyer, R., et al (2016). Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 29(4), 347-358. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • Kakavand, H., Wilmott, J., Long, G., Scolyer, R. (2016). Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 48(2), 194-202. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521.
  • Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2015). Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<01 mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 22(9), 2972-2977. [More Information]
  • Kiyohara, E., Donovan, N., Takeshima, L., Huang, S., Wilmott, J., Scolyer, R., Jones, P., Somers, E., O’Shannessy, D., Hoon, D. (2015). Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 8(2), 111-118. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Chi, M., Guo, S., Wilmott, J., Guo, X., Yan, X., Wang, C., Liu, X., Jin, L., Tseng, H., Liu, T., Scolyer, R., et al (2015). INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 6(37), 39891-39907. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Sanborn, J., Chung, J., Purdom, E., Wang, N., Kakavand, H., Wilmott, J., Butler, T., Thompson, J., Mann, G., Haydu, L., Saw, R., Scolyer, R., et al (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(35), 10995-11000. [More Information]
  • Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J., Gartner, J., Di Pizio, A., Winograd-Katz, S., Mann, G., Scolyer, R., et al (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408-1410. [More Information]
  • Liu, X., Lai, F., Yan, X., Jiang, C., Guo, S., Wang, C., Croft, A., Tseng, H., Wilmott, J., Scolyer, R., et al (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 75(8), 1736-1748. [More Information]
  • Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
  • Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
  • Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]
  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell & Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Marzese, D., Scolyer, R., Roqué, M., Vargas-Roig, L., Huynh, J., Wilmott, J., Murali, R., Buckland, M., Barkhoudarian, G., Thompson, J., et al (2014). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 16(11), 1499-1509. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Liu, Y., Lai, F., Wilmott, J., Yan, X., Liu, X., Luan, Q., Guo, S., Jiang, C., Tseng, H., Scolyer, R., et al (2014). Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 5(22), 11237-11251.
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33(39), 4756-4766. [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]
  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]
  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]
  • Busam, K., Murali, R., Pulitzer, M., McCarthy, S., Thompson, J., Shaw, H., Brady, M., Coit, D., Dusza, S., Wilmott, J., Scolyer, R., et al (2009). Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 33(9), 1386-1395. [More Information]
  • Shingde, M., Buckland,, M., Busam, K., McCarthy, S., Wilmott, J., Thompson, J., Scolyer, R. (2009). Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 62(10), 915-919. [More Information]
  • Howman-Giles, R., Shaw, H., Scolyer, R., Murali, R., Wilmott, J., McCarthy, S., Uren, R., Thompson, J. (2009). Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 17(1), 138-143. [More Information]

Conferences

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

2016

  • Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Diagnostic Histopathology, 69(4), 680-686. [More Information]
  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, C., Lambie, D., Wilmott, J., Pinder, A., Pavey, S., Le Cao, K., Akalin, T., Karaarslan, I., Ozdemir, F., Scolyer, R., et al (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell & Melanoma Research, 29(4), 885-898. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Bosisio, F., Wilmott, J., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W., Massi, D., Thompson, J., Scolyer, R., et al (2016). Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 29(4), 347-358. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • Kakavand, H., Wilmott, J., Long, G., Scolyer, R. (2016). Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 48(2), 194-202. [More Information]

2015

  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521.
  • Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2015). Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<01 mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 22(9), 2972-2977. [More Information]
  • Kiyohara, E., Donovan, N., Takeshima, L., Huang, S., Wilmott, J., Scolyer, R., Jones, P., Somers, E., O’Shannessy, D., Hoon, D. (2015). Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 8(2), 111-118. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Chi, M., Guo, S., Wilmott, J., Guo, X., Yan, X., Wang, C., Liu, X., Jin, L., Tseng, H., Liu, T., Scolyer, R., et al (2015). INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 6(37), 39891-39907. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Sanborn, J., Chung, J., Purdom, E., Wang, N., Kakavand, H., Wilmott, J., Butler, T., Thompson, J., Mann, G., Haydu, L., Saw, R., Scolyer, R., et al (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(35), 10995-11000. [More Information]
  • Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J., Gartner, J., Di Pizio, A., Winograd-Katz, S., Mann, G., Scolyer, R., et al (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408-1410. [More Information]
  • Liu, X., Lai, F., Yan, X., Jiang, C., Guo, S., Wang, C., Croft, A., Tseng, H., Wilmott, J., Scolyer, R., et al (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 75(8), 1736-1748. [More Information]
  • Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
  • Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
  • Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]

2014

  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell & Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Marzese, D., Scolyer, R., Roqué, M., Vargas-Roig, L., Huynh, J., Wilmott, J., Murali, R., Buckland, M., Barkhoudarian, G., Thompson, J., et al (2014). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 16(11), 1499-1509. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Liu, Y., Lai, F., Wilmott, J., Yan, X., Liu, X., Luan, Q., Guo, S., Jiang, C., Tseng, H., Scolyer, R., et al (2014). Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 5(22), 11237-11251.
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33(39), 4756-4766. [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.

2013

  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]

2012

  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]

2011

  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]

2009

  • Busam, K., Murali, R., Pulitzer, M., McCarthy, S., Thompson, J., Shaw, H., Brady, M., Coit, D., Dusza, S., Wilmott, J., Scolyer, R., et al (2009). Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 33(9), 1386-1395. [More Information]
  • Shingde, M., Buckland,, M., Busam, K., McCarthy, S., Wilmott, J., Thompson, J., Scolyer, R. (2009). Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 62(10), 915-919. [More Information]
  • Howman-Giles, R., Shaw, H., Scolyer, R., Murali, R., Wilmott, J., McCarthy, S., Uren, R., Thompson, J. (2009). Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 17(1), 138-143. [More Information]

2008

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

To update your profile click here. For support on your academic profile contact .